Biotechnology & Medical Research

Page 1

Auris Medical Holding AG announces exercise of IPO over-allotment option

Tuesday, 19 Aug 2014 11:17am EDT

Auris Medical Holding AG:Announced that the underwriters of its initial public offering have exercised their over-allotment option to purchase an additional 713,235 shares of common stock.Option yields the company additional gross proceeds of $4.28 million, or $3.98 million less underwriting discounts, and increases the company's number of outstanding shares to 28,954,510.Jefferies LLC and Leerink Partners LLC acted as joint book-running managers for the offering.

Celladon Corp announces closing of public offering of common stock and exercise in full of underwriters' option to purchase additional shares

Monday, 18 Aug 2014 04:05pm EDT

Celladon Corp:Announces closing of its underwritten public offering of 4,600,000 shares of its common stock at $9.50 per share, including 600,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares.Results in gross proceeds from the offering of $43.7 million before deducting underwriting discounts and commissions and other offering expenses payable by Celladon.Credit Suisse and Jefferies LLC acted as joint book-running managers for the offering and Stifel and Wedbush PacGrow Life Sciences acted as co-managers.

Insmed Inc announces closing of public offering and exercise of option to purchase additional shares

Monday, 18 Aug 2014 12:15pm EDT

Insmed Inc:Announces the closing of a $115.1 million underwritten public offering of 10,235,000 shares of common stock, including 1,335,000 shares of common stock which were issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a price of $11.25 per share to the public.Net proceeds to Insmed from this offering were about $108 million.Intends to use the net proceeds from this offering to fund further clinical development of ARIKAYCE(tm), or liposomal amikacin for inhalation, to treat nontuberculous mycobacteria (NTM) lung disease patients and Pseudomonas aeruginosa lung infections in cystic fibrosis (CF) patients.Also intends to use net proceeds to fund its efforts to obtain regulatory approvals and commercialize ARIKAYCE for NTM patients and Pseudomonas aeruginosa in CF patients.Also intends to use net proceeds to invest in increased third-party manufacturing capacity in anticipation of possible commercial launch of ARIKAYCE in Europe and the United States.Also intends to use the net proceeds balance to fund working capital, capital expenditures, general research and development, and other general corporate purposes, which may include the acquisition or in-license of additional compounds, product candidates, technology or businesses.Leerink Partners LLC acted as sole book-running manager, Piper Jaffray & Co. and JMP Securities LLC acted as lead managers, and H.C. Wainwright & Co., LLC acted as co-manager for the offering.

Aqualis launching 100 million Norwegian crowns share issue

Monday, 18 Aug 2014 02:20am EDT

Aqualis ASA:Says offering 158,731,159 new shares at subscription price of 0.63 Norwegian crown, to raise gross proceeds of 100 million Norwegian crowns.Says net proceeds from the Rights Issue shall be used to part refinance existing bank loans in Weifa and general corporate purposes.Says subscription period commences on Aug. 18 and expires on Sep. 1 at 16:30 CET.

Regeneus Ltd to issue ordinary shares

Friday, 15 Aug 2014 04:07am EDT

Regeneus Ltd:To issue 10,769,230 fully paid ordinary shares, at A$0.26 per share.Says private placement to raise funds to be used to accelerate product development.

Leaf Energy Ltd to issue ordinary shares

Friday, 15 Aug 2014 03:11am EDT

Leaf Energy Ltd:To issues 9,642,854 fully paid ordinary shares, at A$0.035 per share.Purpose of issue is to continue research and development of Leaf Energy's Glycell process, continue development of Leaf Energy's IP rights and patent position and pursue commercialisation of Glycell process.

Neuren Pharmaceuticals Ltd to issue ordinary shares

Friday, 15 Aug 2014 02:59am EDT

Neuren Pharmaceuticals Ltd:To issues 2,106,173 fully paid ordinary shares.To issues 2,006,173 at A$0.0194 per share and 100,000 at A$0.019 per share.Purpose of issue is to exercise of options to acquire ordinary shares.

Genomics BioSci & Tech. Co., Ltd. to issue new share

Thursday, 14 Aug 2014 09:00am EDT

Genomics BioSci & Tech. Co., Ltd:To issue up to 10 million new shares of its common stock.New shares with par value of T$10 per share and tentative issue price at T$40 per share.15 pct of the new shares to be offered to the company's employees.Remaining 85 pct to be offered to the existing shareholders.Proceeds to be used for buying machinery equipment, investment in subsidiary, strategic alliance and repaying bank loan.

Insmed Inc announces pricing of public offering of common stock

Tuesday, 12 Aug 2014 07:26pm EDT

Insmed Inc:Says that it has priced an offering of 8.9 million shares of its common stock at a price of $11.25 per share in a registered underwritten public offering for gross proceeds totaling about $100 million.Says all of the shares in the offering are being sold by Insmed.Says net proceeds to Insmed from this offering are expected to be about $94 million, after deducting underwriting discounts and commissions, and other estimated offering expenses payable by Insmed.Says the offering is expected to close on or about Aug. 18, 2014.Insmed intends to use the net proceeds from this offering to fund further clinical development of ARIKAYCE, or liposomal amikacin for inhalation, to treat nontuberculous mycobacteria lung disease patients and Pseudomonas aeruginosa lung infections in cystic fibrosis (CF) patients.To fund its efforts to obtain regulatory approvals and commercialize ARIKAYCE for NTM patients and Pseudomonas aeruginosa in CF patients.To invest in increased third-party manufacturing capacity in anticipation of possible commercial launch of ARIKAYCE in Europe and the United States, and the balance.To fund working capital, capital expenditures, general research and development, and other general corporate purposes, which may include the acquisition or in-license of additional compounds, product candidates, technology or businesses.

Celladon Corp announces pricing of public offering of common stock

Tuesday, 12 Aug 2014 06:06pm EDT

Celladon Corp:Prices underwritten public offering of 4,000,000 shares of common stock at $9.50 per share.Gross proceeds to Celladon from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Celladon, are expected to be about $38.0 mln.Celladon has also granted the underwriters a 30-day option to purchase up to an aggregate of 600,000 additional shares of common stock.Offering is scheduled to close on Aug. 18.Celladon anticipates using net proceeds from offering to fund research and development activities and for working capital and general corporate purposes.Credit Suisse and Jefferies LLC are acting as joint book-running managers for offering and Stifel and Wedbush PacGrow Life Sciences are acting as co-managers.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.